Opinion|Videos|August 21, 2024
Real Life Clinical Practice Use of Selinexor: Dosing Strategies, Supportive Care, and Strategies to Incorporate into Novel Selinexor-Based Regimens
The key opinion leaders examine selinexor combinations and dosing strategies they currently employ, while also addressing how the frequency of treatment-related adverse events (TRAEs) associated with selinexor varies with lower dosing regimens in the context of managing early relapse multiple myeloma.
Advertisement
Video content above is prompted by the following:
- What selinexor combinations & doses are you currently using in your clinical practice?
- What has your experience been with selinexor based-regimens? How have the frequency of TRAEs associated with Selinexor differed with lower dosing?
- What has your experience been with selinexor based-regimens? How have the frequency of TRAEs associated with Selinexor differed with lower dosing?
- Please comment on any differences or similarities between your Selinexor prescribing patterns & experiences.
Advertisement
Related to this article
An OncLive Scientific Interchange and Workshop covered sequencing, toxicity management, and access barriers for CAR T-cell therapy in multiple myeloma.
Readouts across LBCL, relapsed/refractory myeloma, and CALR-mutated myelofibrosis anchored the hematology data presented at EHA 2026.
The FDA accepted a new drug application for mezigdomide plus carfilzomib and dexamethasone for relapsed/refractory multiple myeloma.
In case you missed any, check out our recap of the episodes of OncLive On Air that aired in June 2026.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
The FDA approved subcutaneous isatuximab delivered via an on-body injector for multiple myeloma.
Hematologic oncology experts outline the top data and themes to emerge from the 2026 EHA Congress
Andrew Spencer, MBBS, FRACP, FRCPA, DM, breaks down phase 1 data for in vivo CAR T-cell therapy in relapsed/refractory multiple myeloma.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Gedatolisib Plus Fulvestrant ± Palbociclib for Hormone Receptor–Positive, HER2-Negative, Locally Advanced/Metastatic Breast Cancer
2
FDA Awards Traditional Approval to Selpercatinib for RET+ Advanced Solid Tumors
3
FDA Grants Fast Track Designation to SOT109 in Advanced Colorectal Cancer
4
Research Rewind: Notable Phase 1/2 Breast Cancer Trial Readouts From Quarter 2 of 2026
5